Here's how NCBI.NLM.NIH.GOV makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

NCBI . NLM . NIH . GOV {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Ncbi.nlm.nih.gov Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Social Networks
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. Hosting Providers
  14. CDN Services

We began analyzing https://pmc.ncbi.nlm.nih.gov/articles/PMC8424653/, but it redirected us to https://pmc.ncbi.nlm.nih.gov/articles/PMC8424653/. The analysis below is for the second page.

Title[redir]:
Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer - PMC
Description:
Increased levels of total tumor-infiltrating lymphocytes (TILs) are generally associated with good prognosis in several breast cancer subtypes. Subtypes of TILs impact both tumor cells and immune cells in a variety of different ways, leading to ...

Matching Content Categories {📚}

  • Science
  • Health & Fitness
  • Education

Content Management System {📝}

What CMS is ncbi.nlm.nih.gov built with?

Custom-built

No common CMS systems were detected on Ncbi.nlm.nih.gov, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of ncbi.nlm.nih.gov audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Ncbi.nlm.nih.gov Make Money? {💸}

We don’t know how the website earns money.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Ncbi.nlm.nih.gov could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

cells, doi, cancer, breast, google, scholar, pubmed, patients, pmc, article, free, cell, tumor, tregs, clinical, levels, regulatory, response, treatment, human, phase, immune, effector, therapy, lymphocytes, expression, journal, research, tumorinfiltrating, memory, survival, receptor, prognosis, tumors, tnbc, immunol, natural, activity, trm, subtypes, tils, target, study, trastuzumab, nature, antitumor, antigen, blood, nct, killer,

Topics {✒️}

fda%20grants%20accelerated%20approval%20to%20pembrolizumab%20for%20locally%20recurrent databases/fda-grants-accelerated-approval-pembrolizumab-locally-recurrent-unresectable metastatic%20triple%20negative%20breast%20cancer&text= p53-peptide-pulsed dendritic cells pd-1/pd-l1 axis text=approvals%20and%20databases differentiates α/β tcr-positive anti–pd-1/pd-l1 therapy anti-pd-l1 antibody avelumab shorter metastasis-free survival her2/neu-expressing malignancies tumor-specific tissue-resident memory t-cell metagene predicts triple-negative breast cancer induce tgf-β-dependent conversion hla-a2-binding peptide vaccination her2-derived peptide administered node-negative breast cancer 2/neu protein-specific antibody %20november%2013%2c%202020%2c%20the keytruda%2c%20merck%20%26%20co triple-negative breast cancers anti-cd3/cd28 promotes b-cell targeted therapy anti-pd-l1 immunotherapy demonstrated locally recurrent unresectable dc-based vaccines directed phospholipase cgamma-dependent pathway 3-year progression-free survival natural killer-mediated cytotoxicity anti-pd-l1 antibodies muc1-specific igg antibodies cd4+cd25+foxp3+ human regulatory anti-pd-l1 mab anti-pd-l1 antibody forkhead/winged-helix protein chimeric antigen receptor-modified breast cancer—adverse events h-2-deficient lymphoma variants anti-pd-l1 therapy tumor antigen-specific immunoglobin double-negative breast cancer pd-1/pd-l1 blockade ccr7-stimulated dcs migrate pmc beta search upregulating pd-l1 expression pd-l1 expression correlates cd8+cd103+ tumor-infiltrating lymphocytes tumors express pd-l1 β-d-mannuronic acid

Questions {❓}

  • Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?

Social Networks {👍}(6)

External Links {🔗}(424)

Analytics and Tracking {📊}

  • Google Analytics
  • Google Analytics 4
  • Google Tag Manager

Libraries {📚}

  • jQuery
  • jQuery module (jquery-3.6.0)
  • Zoom.js

Emails and Hosting {✉️}

Mail Servers:

  • nihcesxway.hub.nih.gov
  • nihcesxway2.hub.nih.gov
  • nihcesxway3.hub.nih.gov
  • nihcesxway4.hub.nih.gov
  • nihcesxway5.hub.nih.gov

Name Servers:

  • dns1-ncbi.ncbi.nlm.nih.gov
  • dns2-ncbi.ncbi.nlm.nih.gov
  • lhcns1.nlm.nih.gov
  • lhcns2.nlm.nih.gov

CDN Services {📦}

  • Ncbi

4.87s.